0000950170-24-051488.txt : 20240501
0000950170-24-051488.hdr.sgml : 20240501
20240501193634
ACCESSION NUMBER: 0000950170-24-051488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240429
FILED AS OF DATE: 20240501
DATE AS OF CHANGE: 20240501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gangloff Scott A.
CENTRAL INDEX KEY: 0001663253
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 24904693
MAIL ADDRESS:
STREET 1: C/O ONCOBIOLOGICS, INC.
STREET 2: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-04-29
0001744659
Akero Therapeutics, Inc.
AKRO
0001663253
Gangloff Scott A.
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Technology Officer
false
Stock Option (Right to Buy)
19.62
2024-04-29
4
A
false
225000
0.00
A
2034-04-28
Common Stock
225000
225000
D
Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Jonathan Young, Attorney-in-fact
2024-05-01